Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 23514842)

1.

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.

Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S.

J Hum Hypertens. 2013 Aug;27(8):479-86. doi: 10.1038/jhh.2013.6. Epub 2013 Mar 21.

2.

Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.

Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S.

J Clin Hypertens (Greenwich). 2012 May;14(5):284-92. doi: 10.1111/j.1751-7176.2012.00616.x. Epub 2012 Mar 6.

PMID:
22533654
3.

Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.

Hypertension. 2012 Aug;60(2):310-8. doi: 10.1161/HYPERTENSIONAHA.111.188284. Epub 2012 Jun 18.

4.

Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S.

J Clin Hypertens (Greenwich). 2011 Jul;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x. Epub 2011 Jun 20.

PMID:
21762358
5.

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S.

Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31.

6.

Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.

Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S.

Am J Med. 2012 Dec;125(12):1229.e1-1229.e10. doi: 10.1016/j.amjmed.2012.05.023. Epub 2012 Aug 30.

PMID:
22939358
7.

Azilsartan medoxomil: a review of its use in hypertension.

Perry CM.

Clin Drug Investig. 2012 Sep 1;32(9):621-39. doi: 10.2165/11209600-000000000-00000. Review.

PMID:
22877322
8.

Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.

Malacco E, Omboni S, Mallion JM, Volpe M; ESPORT Study Group.

High Blood Press Cardiovasc Prev. 2012 Dec;19(4):213-22. doi: 10.1007/BF03297633. Epub 2013 Feb 19.

PMID:
23430666
9.

The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S.

J Clin Hypertens (Greenwich). 2011 Feb;13(2):81-8. doi: 10.1111/j.1751-7176.2010.00425.x.

PMID:
21272195
10.

Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.

Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM.

J Hum Hypertens. 2009 Sep;23(9):610-9. doi: 10.1038/jhh.2009.4. Epub 2009 Feb 19.

PMID:
19225530
11.
12.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
13.

CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.

Spinar J, Vítovec J, Soucek M, Dusek L, Pavlík T; CORD Invesigators.

Vnitr Lek. 2009 May;55(5):481-8.

PMID:
19514614
14.
15.

Azilsartan medoxomil: a new Angiotensin receptor blocker.

Zaiken K, Cheng JW.

Clin Ther. 2011 Nov;33(11):1577-89. doi: 10.1016/j.clinthera.2011.10.007. Epub 2011 Nov 8. Review.

PMID:
22071238
16.

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.

Mallion JM, Omboni S, Barton J, Van Mieghem W, Narkiewicz K, Panzer PK, Puig JG, Stefanadis C, Zweiker R; Study Group.

Blood Press Suppl. 2011 Apr;1:3-11. doi: 10.3109/08037051.2010.532332. Epub 2010 Nov 23.

PMID:
21091270
17.

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.

Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R.

J Int Med Res. 2005;33 Suppl 1:39A-49A.

PMID:
16222899
18.

Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.

Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski JM, Lins R, Rodicio J, Stefenelli T, Woittiez A, Böhm M.

Clin Drug Investig. 2007;27(8):545-58.

PMID:
17638395
19.

A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.

Clin Drug Investig. 2007;27(6):407-17.

PMID:
17506591
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk